89bio, Inc.
ETNB
$9.37
-$0.22-2.29%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.06% | 35.47% | 21.68% | 11.70% | 10.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.88% | 31.25% | 17.98% | 5.55% | 13.94% |
| Operating Income | -47.88% | -31.25% | -17.98% | -5.55% | -13.94% |
| Income Before Tax | -35.60% | -21.84% | -12.56% | -4.18% | -13.00% |
| Income Tax Expenses | 20,252.63% | 111.11% | 112.33% | 112.33% | 112.93% |
| Earnings from Continuing Operations | -39.37% | -22.03% | -12.73% | -4.35% | -13.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.37% | -22.03% | -12.73% | -4.35% | -13.21% |
| EBIT | -47.88% | -31.25% | -17.98% | -5.55% | -13.94% |
| EBITDA | -47.92% | -31.30% | -18.02% | -5.57% | -13.96% |
| EPS Basic | 43.11% | 54.07% | 59.35% | 43.47% | 20.98% |
| Normalized Basic EPS | 43.38% | 52.81% | 58.35% | 42.30% | 19.93% |
| EPS Diluted | 43.11% | 54.07% | 59.35% | 43.47% | 20.98% |
| Normalized Diluted EPS | 43.38% | 52.81% | 58.35% | 42.30% | 19.93% |
| Average Basic Shares Outstanding | 104.92% | 135.15% | 178.07% | 112.48% | 72.53% |
| Average Diluted Shares Outstanding | 104.92% | 135.15% | 178.07% | 112.48% | 72.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
